Simultaneous application of the vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK 222584 and ionizing radiation does not further reduce the growth of canine oral melanoma xenografts in nude mice

被引:3
|
作者
Inteeworn, Natalie [1 ]
Ohlerth, Stefanie
Hoepfl, Gisele
Guscetti, Franco
Bley, Carla Rohrer
Wergin, Melanie C.
Roos, Malgorzata
Gassmann, Max
Kaser-Hotz, Barbara
机构
[1] Univ Zurich, Vetsuisse Fac, Sect Diagnost Imaging & Radiooncol, CH-8006 Zurich, Switzerland
[2] Univ Zurich, Vetsuisse Fac, Inst Vet Physiol, CH-8006 Zurich, Switzerland
[3] Univ Zurich, Vetsuisse Fac, Inst Vet Pathol, CH-8006 Zurich, Switzerland
[4] Univ Zurich, Dept Biostat, Inst Social & Prevent Med, CH-8006 Zurich, Switzerland
来源
VETERINARY JOURNAL | 2007年 / 173卷 / 03期
关键词
melanoma; xenograft; canine; PTK787/ZK; 222584; radiotherapy; power Doppler ultrasonography; pO(2);
D O I
10.1016/j.tvjl.2007.03.001
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
PTK787/ZK 222584 is an inhibitor of the vascular endothelial growth factor (VEGF) receptor tyrosine kinases. In this study, the effectiveness of PTK787/ZK 222584 and radiation on canine oral melanoma xenografts was assessed. Xenografts were treated with radiotherapy (4 x 6 Gy), or with PTK787/ZK 222584, or with a combination of both. Treatment efficacy was assessed using a tumour growth delay assay, serial power Doppler and pO(2) measurements during and after therapy. There was a significant growth delay for the group treated with radiation alone and for the combined treatment group. However, tumour growth delay was similar in both groups. Tumours were hypoxic before irradiation and no significant re-oxygenation occurred during therapy. In all tumours, vascularity and perfusion were significantly lower at the end of the study but no significant differences in perfusion, vascularity and oxygenation status were observed between and within treatment groups. The combination of PTK787/ZK 222584 and radiotherapy did not perform better than radiotherapy alone in this model. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:564 / 570
页数:7
相关论文
共 37 条
  • [21] Phase I trial of PTK787/ZK 222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, in acute myeloid leukemia and myelodysplastic syndrome.
    Roboz, GJ
    List, AF
    Giles, F
    Rae, PE
    Dugan, M
    Greenberg, J
    Osama, S
    Schuster, MW
    Laurent, D
    Feldman, EJ
    BLOOD, 2002, 100 (11) : 337A - 337A
  • [22] Phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK222584 with chemotherapy (oxaliplatin/5-FU/Leucovorin) in patients with advanced colorectal cancer.
    Steward, W
    Wiedenmann, B
    Rosewicz, S
    Peng, B
    Thomas, A
    McClelland, H
    Henry, A
    Desai, P
    Laurent, D
    Dugan, M
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3663S - 3663S
  • [23] Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases
    Lee, L
    Sharma, S
    Morgan, B
    Allegrini, P
    Schnell, C
    Brueggen, J
    Cozens, R
    Horsfield, M
    Guenther, C
    Steward, WP
    Drevs, J
    Lebwohl, D
    Wood, J
    McSheehy, PMJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (06) : 761 - 771
  • [24] Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases
    Lucy Lee
    Sunil Sharma
    Bruno Morgan
    Peter Allegrini
    Christian Schnell
    Josef Brueggen
    Robert Cozens
    Mark Horsfield
    Clemens Guenther
    Will P. Steward
    Joachim Drevs
    David Lebwohl
    Jeanette Wood
    Paul M. J. McSheehy
    Cancer Chemotherapy and Pharmacology, 2006, 57 : 761 - 771
  • [25] Decreased in-vitro cellular drug resistance by addition of vascular endothelial growth factor receptor (VEGFR) inhibitor, PTK787/ZK 222584, to conventional chemotherapy in pediatric AML.
    De Bont, ESJM
    Meeuwsen-de Boer, T
    Scherpen, F
    Streefland, E
    Kamps, WA
    LEUKEMIA, 2003, 17 (03) : 668 - 668
  • [26] Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials
    Drevs, J
    Zirrgiebel, U
    Schmidt-Gersbach, CIM
    Mross, K
    Medinger, M
    Lee, L
    Pinheiro, J
    Wood, J
    Thomas, AL
    Unger, C
    Henry, A
    Steward, WP
    Laurent, D
    Lebwohl, D
    Dugan, M
    Marmé, D
    ANNALS OF ONCOLOGY, 2005, 16 (04) : 558 - 565
  • [27] The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584
    Qian, DZ
    Wang, XF
    Kachhap, SK
    Kato, Y
    Wei, YF
    Zhang, L
    Atadja, P
    Pili, R
    CANCER RESEARCH, 2004, 64 (18) : 6626 - 6634
  • [28] Defining the biologically active dose for PTK787/ZK222584 (PTK/ZK), a vascular endothelial growth factor (VEGF) receptor inhibitor, based on the assessment of two biomarkers [dynamic contrast enhanced magnetic resonance imaging (DCE-MRI), plasma VEGF] in two phase I studies
    Morgan, B
    Drevs, J
    Steward, WP
    Lee, L
    DiLea, C
    Marme, D
    Mross, K
    Thomas, A
    Laurent, D
    Dugan, M
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S75 - S75
  • [29] PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging
    Drevs, J
    Müller-Driver, R
    Wittig, C
    Fuxius, S
    Esser, N
    Hugenschmidt, H
    Konerding, MA
    Allegrini, PR
    Wood, J
    Hennig, J
    Unger, C
    Marme, D
    CANCER RESEARCH, 2002, 62 (14) : 4015 - 4022
  • [30] PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma turnours and inhibits their growth in vivo
    Rudin, M
    McSheehy, PMJ
    Allegrini, PR
    Rausch, M
    Baumann, D
    Becquet, M
    Brecht, K
    Brueggen, J
    Ferretti, S
    Schaeffer, F
    Schnell, C
    Wood, J
    NMR IN BIOMEDICINE, 2005, 18 (05) : 308 - 321